Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

235.27
-0.1500-0.06%
Post-market: 236.761.49+0.63%16:49 EDT
Volume:9.04M
Turnover:2.12B
Market Cap:566.83B
PE:21.33
High:236.00
Open:234.14
Low:232.24
Close:235.42
52wk High:251.71
52wk Low:141.50
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.98
T/O Rate:0.38%
Dividend:5.14
Dividend Rate:2.18%
EPS(TTM):11.03
EPS(LYR):11.03
ROE:35.03%
ROA:8.68%
PB:6.95
PE(LYR):21.32

Loading ...

Perrigo Co. PLC Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Mar 14

J&J says erdafitinib met primary safety endpoint in Phase 1 study

TIPRANKS
·
Mar 14

Johnson & Johnson Phase 1 Erda-iDRS trial reports 89% complete response rate in intermediate-risk bladder cancer

Reuters
·
Mar 14

Johnson & Johnson Highlights Promising First-in-Human Erda-Idrs (Formerly Tar-210) Results in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

THOMSON REUTERS
·
Mar 14

Is Johnson & Johnson (JNJ) Pricing Reflect Its Strong Multi‑Year Rally And Legal Headline Risks

Simply Wall St.
·
Mar 13

Perrigo Co. PLC Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Mar 13

Johnson & Johnson wins FDA approval for TECNIS PureSee intraocular lens in U.S. cataract surgery

Reuters
·
Mar 12

J&J - Tecnis Puresee Iol to Be Available in U.S. Later This Year

THOMSON REUTERS
·
Mar 12

Johnson & Johnson Announces FDA Approval of Tecnis Puresee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

THOMSON REUTERS
·
Mar 12

Johnson & Johnson Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 11

Johnson & Johnson Announces Annual Shareholder Meeting

Reuters
·
Mar 11

Johnson & Johnson publishes 2025 annual report with USD 94.2 billion sales

Reuters
·
Mar 11

BRIEF-J&J Says CEO's 2025 Total Compensation Was $32.8 Million

Reuters
·
Mar 11

J&J: CEO 2025 Total Compensation $32.8 Mln- SEC Filing

THOMSON REUTERS
·
Mar 11

Citigroup Adjusts Price Target on Johnson & Johnson to $274 From $250, Maintains Buy Rating

MT Newswires Live
·
Mar 11

Johnson & Johnson price target raised to $274 from $250 at Citi

TIPRANKS
·
Mar 11

Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)

TIPRANKS
·
Mar 11

Perrigo Co. PLC Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Mar 11

A Look At Johnson & Johnson (JNJ) Valuation After New Multiple Myeloma FDA Approval

Simply Wall St.
·
Mar 11

Johnson & Johnson treatment of multiple myeloma granted orphan designation

TIPRANKS
·
Mar 10